Our most-read retinal coverage of 2025 highlights how long-term data and treatment innovations are influencing clinical practice. From 5-year real-world outcomes with aflibercept in central retinal vein occlusion to insights on post-injection follow-up and extended-interval dosing in neovascular age-related macular degeneration, these articles reflect continued progress toward durable efficacy with fewer treatment burdens.
Five-year study shows sustained benefits of aflibercept for macular edema due to CRVO
A real-world analysis found that intravitreal aflibercept delivered sustained visual acuity gains and durable anatomic improvements in patients with macular edema due to central retinal vein occlusion over five years. About half of patients achieved a good long-term response, with favorable outcomes linked to baseline retinal integrity and the ability to extend treatment intervals.
Read the full article here.
Blurred vision most common cause of unscheduled follow-up after intravitreal injections
A retrospective study found that urgent follow-up visits within 7 days of intravitreal injection were uncommon and most often driven by patient-reported blurred vision. Among more than 73,000 injections, urgent visits occurred in 0.6% of cases, with symptoms typically arising within the first few days after treatment.
Read the full article here.
Aflibercept 8 mg maintains efficacy with fewer injections in nAMD patients through 96 weeks
Ninety-six–week results from the phase 3 PULSAR trial show that aflibercept 8 mg given at 12- or 16-week intervals delivers visual and anatomic outcomes comparable to standard aflibercept 2 mg every 8 weeks in treatment-naive neovascular age-related macular degeneration. The extended-dose regimens reduced injection frequency while maintaining a similar safety profile.
Read the full article here.
Related Content
